【佳學基因檢測】腫瘤學中寡核苷酸治療的賊新進展
腫瘤基因檢測十大公司排序
閱讀腫瘤基因解碼協(xié)會如何提升基因檢測的正確性知悉《PLoS One》在?2021; 16(2): e0247090發(fā)表了一篇題目為《腫瘤學中寡核苷酸治療的賊新進展》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Sadaaki Nishimura, Conceptualization, Data curation, Investigation, Software, Visualization, Writing – original draft, Atsushi Sugimoto, Data curation, Shuhei Kushiyama, Data curation, Shingo Togano, Data curation, Investigation, Kenji Kuroda, Data curation, Resources, Yurie Yamamoto, Data curation, Makoto Yamauchi, Data curation, Resources,? Toshiyuki Sumi, Data curation, Resources,? Hiroyasu Kaneda, Data curation, Resources,? Tomoya Kawaguchi, Data curation, Investigation,? Minoru Kato, Data curation, Formal analysis, Investigation,? Mizuki Tagami, Data curation, Formal analysis,? Naoto Oebisu, Data curation, Project administration,? Manabu Hoshi, Data curation, Investigation,? Kenjiro Kimura, Data curation, Investigation,? Shoji Kubo, Data curation, Investigation,? Kazuya Muguruma, Data curation, Formal analysis,? Tsutomu Takashima, Data curation, Formal analysis,? Masaichi Ohira, Data curation, Investigation, and Masakazu Yashiro, Project administration, Resources, Supervision, Writing – review & editing,等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展,進一步強調(diào)了基因信息檢測與分析的重要性。
腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞:
反義寡核苷酸,siRNA,適體,DNA核酶,癌癥
腫瘤靶向治療基因檢測臨床應(yīng)用結(jié)果
癌癥是全球主要的死亡原因之一。在過去的幾十年里,包括手術(shù)、放射和化學療法在內(nèi)的傳統(tǒng)療法已經(jīng)提高了許多類型癌癥的存活率。然而,癌癥反復(fù)和/或轉(zhuǎn)移到遠處器官仍然是主要挑戰(zhàn),導致大量未滿足的臨床需求。寡核苷酸療法,包括反義寡核苷酸、小干擾 RNA 和適體,在杜氏肌營養(yǎng)不良癥、家族性淀粉樣神經(jīng)病和黃斑變性等疾病適應(yīng)癥方面顯示出有希望的臨床結(jié)果。雖然目前還沒有批準用于任何類型癌癥的寡核苷酸藥物,但在臨床前研究和臨床試驗中獲得的結(jié)果令人鼓舞。在這里,我們概述了腫瘤學中寡核苷酸治療領(lǐng)域的賊新進展,回顧了當前的臨床試驗,并討論了相關(guān)挑戰(zhàn)。關(guān)鍵詞:反義寡核苷酸、siRNA、適體、脫氧核糖核酸酶、癌癥
腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述:
antisense oligonucleotides, siRNA, aptamers, DNAzymes, cancers
(責任編輯:佳學基因)